These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18383050)

  • 1. Update on atrial fibrillation: part II.
    Savelieva I; Camm J
    Clin Cardiol; 2008 Mar; 31(3):102-8. PubMed ID: 18383050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antiarrhythmic drugs for the treatment of atrial fibrillation.
    Castro A; Bianconi L; Santini M
    Pacing Clin Electrophysiol; 2002 Feb; 25(2):249-59. PubMed ID: 11916001
    [No Abstract]   [Full Text] [Related]  

  • 3. Newer antiarrhythmic drugs.
    Gupta AK; Maheshwari A; Thakur RK; Lokhandwala YY
    Indian Heart J; 2001; 53(3):354-60. PubMed ID: 11516042
    [No Abstract]   [Full Text] [Related]  

  • 4. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
    Singh S
    J Interv Card Electrophysiol; 2004; 10 Suppl 1():71-6. PubMed ID: 14739742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
    Conway E; Musco S; Kowey PR
    Am J Cardiol; 2008 Sep; 102(6A):12H-19H. PubMed ID: 18790110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical management of atrial fibrillation: state of the art.
    Camm J
    J Cardiovasc Electrophysiol; 2006 Sep; 17 Suppl 2():S2-6. PubMed ID: 16939435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil.
    Krishnamoorthy S; Lip GY
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1191-6. PubMed ID: 19604120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drug therapy of atrial fibrillation: focus on new agents.
    Dorian P
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8 Suppl 1():S27-31. PubMed ID: 12746749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical differences between the newer antiarrhythmic agents.
    Camm AJ
    Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiarrhythmic agents for atrial fibrillation.
    Conway DS; Lip GY
    Curr Opin Investig Drugs; 2001 Jan; 2(1):87-92. PubMed ID: 11527018
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.
    Pritchett EL; Page RL; Connolly SJ; Marcello SR; Schnell DJ; Wilkinson WE
    J Am Coll Cardiol; 2000 Sep; 36(3):794-802. PubMed ID: 10987602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antiarrhythmic treatment of atrial fibrillation.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Gonzalez MD
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):707-14. PubMed ID: 17605649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
    Pritchett EL; Kowey P; Connolly S; Page RL; Kerr C; Wilkinson WE;
    Am Heart J; 2006 May; 151(5):1043-9. PubMed ID: 16644334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial.
    Lombardi F; Borggrefe M; Ruzyllo W; Lüderitz B;
    Eur Heart J; 2006 Sep; 27(18):2224-31. PubMed ID: 16935870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azimilide for atrial fibrillation: clinical trial results and implications.
    Pritchett EL; Marcello SR
    Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments.
    Papp JG; Singh BN
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8 Suppl 1():S1-3. PubMed ID: 12746746
    [No Abstract]   [Full Text] [Related]  

  • 17. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
    Wang J; Feng J; Nattel S
    Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.
    Fischbach PS; Barrett TD; Goyal R; Tran BC; Syed ZA; Hennan JK; Lucchesi BR
    J Cardiovasc Electrophysiol; 2001 Oct; 12(10):1138-44. PubMed ID: 11699522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Basic mechanisms of the new antiarrhythmic drugs in atrial fibrillation].
    Filgueiras-Rama D; Castrejón S; Calvo C; Estrada A; Doiny D; Ortega M; Berenfeld O; Merino JL; Jalife J
    Arch Cardiol Mex; 2012; 82(2):139-52. PubMed ID: 22735655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.